IRAK4-IN-28 manufacturers
- IRAK4-IN-28
-
- $3400.00
-
2026-05-11
- CAS:2952532-92-0
- Purity:
- Supply Ability: 10g
|
| | IRAK4-IN-28 Basic information |
| | IRAK4-IN-28 Chemical Properties |
| density | 1.544±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 6.901±0.46(predicted) |
| | IRAK4-IN-28 Usage And Synthesis |
| Uses | IRAK4-IN-28 (compound 42) is an orally active IRAK4 inhibitor (IC50=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases[1]. | | in vivo | IRAK4-IN-28 (compound 42) has favorable pharmacokinetic properties in the SD rat model[1].
IRAK4-IN-28 has orally bioactive with 68% availability[1].
IRAK4-IN-28 (50 or 100 mg/ml, single dose, oral ) significantly reduces LPS-induced TNF-α and IL-6 cytokines release in the mouse model[1].
Pharmacokinetic Analysis in male SD Rat Model[1]
| Route | Dose (mg/kg) | Clobs (mL·h/kg) | Clmax (ng/mL) | Vss_obs (L/kg) | AUClast (ng·h/mL) | t1/2 (h) | Tmax (h) | F (%) | | i.v. | 2 | 21 | / | 3.2 | 1520 | 1.8 | / | / | | p.o. | 10 | / | 1133 | / | 5196 | / | 1.7 | 68 |
| Animal Model: | LPS-stimulated female C57BL/6 mice[1] | | Dosage: | 50 or 100 mg/ml, single dose; 1 h prior to 1 mg/kg LPS administration by intraperitoneal injection | | Administration: | Oral gavage (p.o.) | | Result: | Inhibited cytokine TNF-α and IL-6 in a dose-dependent manner in an LPS-stimulated mouse model. |
| | References | [1] Yongjin Hao, et al. Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model. Bioorg Chem. 2023 , 137:106584. DOI:10.1016/j.bioorg.2023.106584 |
| | IRAK4-IN-28 Preparation Products And Raw materials |
|